Global Diabetic Macular Edema Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product Type;

Intravitreal Injections and Intravitreal Implants.

By Therapy Type;

Anti-VEGF, Corticosteroids, and Other Off-label Drugs [Triamcinolone].

By Distribution Channel;

Hospital Pharmacy, Retail Pharmacy, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn840604237 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Diabetic Macular Edema Market (USD Million), 2021 - 2031

In the year 2024, the Global Diabetic Macular Edema Market was valued at USD 3,764.74 million. The size of this market is expected to increase to USD 4,236.25 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 1.7%.

The global diabetic macular edema (DME) market is experiencing substantial growth as the prevalence of diabetes continues to rise, leading to an increase in diabetes-related complications. Diabetic macular edema, a common cause of vision loss in diabetic patients, occurs when blood vessels in the retina become damaged and leak fluid, causing the macula to swell. With the number of individuals living with diabetes projected to rise significantly in the coming years, the demand for effective treatments for DME is expected to increase correspondingly. This burgeoning need is driving innovation and investment in the DME treatment market.

A major factor contributing to the growth of the DME market is the development and approval of advanced therapeutic options. Over the past decade, significant progress has been made in the treatment of DME, with the introduction of anti-VEGF (vascular endothelial growth factor) therapies revolutionizing the management of this condition. These therapies, which include drugs like ranibizumab, aflibercept, and bevacizumab, have been shown to improve vision and reduce retinal swelling effectively. The increasing adoption of these advanced therapies is enhancing treatment outcomes for patients and driving market growth.

The market is being propelled by advancements in diagnostic technologies and the integration of personalized medicine approaches. Early and accurate detection of diabetic macular edema is crucial for effective management and preventing severe vision loss. Innovations in imaging technologies, such as optical coherence tomography (OCT), have significantly improved the ability to diagnose DME at an earlier stage. Moreover, personalized treatment plans based on genetic and biomarker profiles are gaining traction, allowing for more targeted and effective interventions. These advancements are improving the standard of care for DME patients and fostering market expansion.

Geographically, the DME market is experiencing growth across various regions, with North America and Europe leading the way due to their advanced healthcare infrastructures and high prevalence of diabetes. In these regions, strong healthcare systems, significant research funding, and the presence of key market players are driving the adoption of innovative treatments. Meanwhile, emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa are also showing promising growth potential. Factors such as increasing healthcare expenditure, growing awareness about diabetes and its complications, and improving access to advanced treatments are contributing to market growth in these regions. As the global burden of diabetes continues to rise, the demand for effective diabetic macular edema treatments is expected to grow, providing ample opportunities for market expansion and innovation.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Therapy Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Diabetic Macular Edema Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Diabetes
        2. Advancements in Medical Technology
        3. Growing Awareness and Screening Programs
      2. Restraints
        1. High Treatment Costs
        2. Side Effects and Complications
        3. Lack of Infrastructure in Developing Regions
      3. Opportunities
        1. Emerging Markets
        2. Development of Novel Therapies
        3. Telemedicine and Remote Monitoring
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Diabetic Macular Edema Market,By Product Type, 2021 - 2031 (USD Million)
      1. Intravitreal Injections
      2. Intravitreal Implants
    2. Global Diabetic Macular Edema Market, By Therapy Type, 2021 - 2031 (USD Million)
      1. Anti-VEGF
      2. Corticosteroids
      3. Other Off-label Drugs [Triamcinolone]
    3. Global Diabetic Macular Edema Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    4. Global Diabetic Macular Edema Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Regeneron Pharmaceuticals, Inc.
      2. Novartis AG
      3. Genentech, Inc. (Roche)
      4. Allergan plc (AbbVie)
      5. Bayer AG
      6. Santen Pharmaceutical Co., Ltd.
      7. Alimera Sciences, Inc.
      8. Kodiak Sciences Inc.
      9. Clearside Biomedical, Inc.
      10. Oxurion NV
  7. Analyst Views
  8. Future Outlook of the Market